Biological and predictive role of ERCC1 polymorphisms in cancer

Crit Rev Oncol Hematol. 2017 Mar:111:133-143. doi: 10.1016/j.critrevonc.2017.01.016. Epub 2017 Jan 28.

Abstract

Excision repair cross-complementation group 1 (ERCC1) is a key component in DNA repair mechanisms and may influence the tumor DNA-targeting effect of the chemotherapeutic agent oxaliplatin. Germline ERCC1 polymorphisms may alter the protein expression and published data on their predictive and prognostic value have so far been contradictory. In the present article we review available evidence on the clinical role and utility of ERCC1 polymorphisms and, in the absence of a 'perfect' trial, what we call the 'sliding doors' trial, we present the data of ERCC1 genotyping in our local patient population. We found a useful predictive value for oxaliplatin-induced risk of anemia.

Keywords: Colorectal cancer; ERCC1; Oxaliplatin; Single nucleotide polymorphisms.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / enzymology*
  • Colorectal Neoplasms / genetics
  • DNA Repair
  • DNA, Neoplasm / genetics
  • DNA-Binding Proteins / chemistry
  • DNA-Binding Proteins / genetics*
  • Endonucleases / chemistry
  • Endonucleases / genetics*
  • Female
  • Humans
  • Middle Aged
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Replication Protein C / chemistry
  • Replication Protein C / genetics
  • Transcription Factors / chemistry
  • Transcription Factors / genetics

Substances

  • DNA, Neoplasm
  • DNA-Binding Proteins
  • Organoplatinum Compounds
  • Rfc1 protein, mouse
  • Transcription Factors
  • Oxaliplatin
  • ERCC1 protein, human
  • Endonucleases
  • Replication Protein C